Patient-reported outcomes from the phase III randomized IMmotion151 trial: Atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma Journal Article


Authors: Atkins, M. B.; Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; Oudard, S.; Uemura, M.; Lam, E. T.; Grüllich, C.; Quach, C.; Carroll, S.; Ding, B.; Zhu, Q. C.; Piault-Louis, E.; Schiff, C.; Escudier, B.
Article Title: Patient-reported outcomes from the phase III randomized IMmotion151 trial: Atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma
Abstract: PURPOSE: Patient-reported outcomes (PRO) were evaluated in the phase III IMmotion151 trial (NCT02420821) to inform overall treatment/disease burden of atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Patients were randomized 1:1 to receive atezolizumab 1,200 mg intravenous (i.v.) infusions every 3 weeks (q3w) plus bevacizumab 15 mg/kg i.v. q3w or sunitinib 50 mg per day orally 4 weeks on/2 weeks off. Patients completed the MD Anderson Symptom Inventory (MDASI), National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and Brief Fatigue Inventory (BFI) at baseline, q3w during treatment, at end of treatment, and during survival follow-up. Longitudinal and time to deterioration (TTD) analyses for core and RCC symptoms and their interference with daily life, treatment side-effect bother, and health-related quality of life (HRQOL) were evaluated. RESULTS: The intent-to-treat population included 454 and 461 patients in the atezolizumab plus bevacizumab and sunitinib arms, respectively. Completion rates for each instrument were 83% to 86% at baseline and ≥ 70% through week 54. Milder symptoms, less symptom interference and treatment side-effect bother, and better HRQOL at most visits were reported with atezolizumab plus bevacizumab versus sunitinib. The TTD HR (95% CI) favored atezolizumab plus bevacizumab for core (HR, 0.50; 0.40-0.62) and RCC symptoms (HR, 0.45; 0.37-0.55), symptom interference (HR, 0.56; 0.46-0.68), and HRQOL (HR, 0.68; 0.58-0.81). CONCLUSIONS: PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacizumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen. ©2020 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 26
Issue: 11
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2020-06-01
Start Page: 2506
End Page: 2514
Language: English
DOI: 10.1158/1078-0432.Ccr-19-2838
PUBMED: 32127394
PROVIDER: scopus
PMCID: PMC8407399
DOI/URL:
Notes: Article -- Export Date: 1 July 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer